These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30567881)

  • 21. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
    Huang Z; Waxman DJ
    Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
    Gu Y; Tingle MD; Wilson WR
    J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
    de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):135-56. PubMed ID: 15379382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
    Huang L; Winger BA; Cheah V; Gingrich D; Marzan F; Lu Y; Cooper JC; Aweeka F; Long-Boyle J
    J Chromatogr Open; 2022 Nov; 2():. PubMed ID: 35875822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of cytotoxic agents in the treatment of immune-mediated diseases of dogs and cats.
    Miller E
    Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):157-60. PubMed ID: 9283239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
    Zhou D; Lu Y; Steiner MS; Dalton JT
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2659-63. PubMed ID: 10991840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human Liver Microsomes.
    Choi JM; Oh SJ; Lee JY; Jeon JS; Ryu CS; Kim YM; Lee K; Kim SK
    Chem Res Toxicol; 2015 May; 28(5):872-85. PubMed ID: 25860621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans.
    Bohnenstengel F; Hofmann U; Eichelbaum M; Kroemer HK
    Eur J Clin Pharmacol; 1996; 51(3-4):297-301. PubMed ID: 9010702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
    Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of cyclophosphamide in dogs and cats.
    Stanton ME; Legendre AM
    J Am Vet Med Assoc; 1986 Jun; 188(11):1319-22. PubMed ID: 3721990
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
    Baldwin A; Huang Z; Jounaidi Y; Waxman DJ
    Arch Biochem Biophys; 2003 Jan; 409(1):197-206. PubMed ID: 12464259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK; Yu L; Maurel P; Waxman DJ
    Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
    Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
    Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
    Huang Z; Roy P; Waxman DJ
    Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.
    Murray M; Butler AM; Stupans I
    J Pharmacol Exp Ther; 1994 Aug; 270(2):645-9. PubMed ID: 8071856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin.
    Eberhart DC; Gemzik B; Halvorson MR; Parkinson A
    Mol Pharmacol; 1991 Nov; 40(5):859-67. PubMed ID: 1944247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes.
    Yamazaki H; Komatsu T; Takemoto K; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2001 Jun; 29(6):794-7. PubMed ID: 11353746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
    Helsby N; Yong M; Burns K; Findlay M; Porter D
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.